Specialized UDP-Glucuronic Acid Inhibitor Development Service at CD BioGlyco

UDP-Glucose dehydrogenase (UGDH) catalyzes the irreversible two-fold oxidation of UDP-glucose to produce UDP-glucuronic acid, which serves as an activated donor of glucuronic acid residues in a variety of biochemical pathways in nature. In mammals, it is a component of the glycosaminoglycans (heparin, hyaluronic acid, and chondroitin sulfate) that form the "matrix" or extracellular medium of connective tissue. In many pathogenic bacterial strains, UDP-glucuronic acid is a component of the organism's polysaccharide capsule. When capsule formation is disrupted, virulent strains of encapsulated bacteria become avirulent. Therefore, the development of inhibitors targeting UDP-glucuronic acid regulates its metabolic pathways and the activities of related enzymes, thereby intervening in specific diseases or pathological processes.

• UGDH is an enzyme that catalyzes the conversion of UDP-glucose to UDP-glucuronide and is a potential therapeutic target. CD BioGlyco uses RNAi technology based on DNA vectors to synthesize siRNA from DNA templates in vivo to effectively inhibit the expression of UGDH in mammalian tumor cells, thereby limiting the growth of tumors in the body. We provide professional services such as the design and construction of siRNA expression vectors, cell culture and transfection, and immune activity analysis.
• CD BioGlyco has mature inhibitor development solutions, and we provide professional competitive inhibitor development services based on UGDH. We obtain high purity and good solubility UDP-glucose analogs through chemical synthesis and optimization, such as UDP-7-deoxy-α-D-glucose-hept-6-pyranose, which contains a methyl ketone at C-6 and cannot be further oxidized by the enzyme, it is a competitive inhibitor of Streptococcus pyogenes dehydrogenase.
• In addition, we provide accurate and reliable activity analysis for developed inhibitors.

Fig.1 Specialized UDP-glucuronic acid inhibitor development service. (CD BioGlyco)

Publication

Technology: RNA interference (RNAi)

Journal: Biotechnology Letters

IF: 2.716

Published: 2005

Results: UGDH catalyzes the production of UDP-glucuronide, and the authors used RNAi technology to knock down the expression of human UGDH. The siRNA of human UGDH was put into the pRNA-U6.1/Neo vector and chemically transfected into breast cancer cells. The results displayed that the expression of UGDH in the cells was effectively knocked down by RNAi at the protein level.

Fig.2 Construction of pU6-sihUGDH. (Huh, et al., 2005)

Applications

• Detoxification drug development: By inhibiting UDP-glucuronide synthesis or related enzyme activity, the detoxification metabolic pathway is interfered with, thereby increasing the toxicity of specific toxins. This strategy is applied to develop detoxifying drugs to manage poisoning events or to enhance the safety of certain drug treatments.
• Tumor treatment aid research: Tumor cells often have enhanced detoxification capabilities, making them resistant to the effects of chemotherapy drugs. By inhibiting UDP-glucuronide synthesis or related enzyme activity, the ability of tumor cells to detoxify drugs is reduced and the efficacy of chemotherapy is enhanced.
• Drug metabolism regulation: Some drugs need to be converted and eliminated through the UDP-glucuronide metabolism pathway. By interfering with UDP-glucuronide synthesis or related enzyme activity, the metabolic pathway and rate of the drug are modulated, thereby affecting the efficacy and tolerability of the drug.

Advantages

• CD BioGlyco has a professional enzyme technology development means, and our scientists develop UDP-glucuronide inhibitors flexibly and efficiently.
• CD BioGlyco will evaluate the activity and effect of the developed inhibitors from multiple perspectives and provide comprehensive data support.
• CD BioGlyco provides personalized service solutions based on research goals, we flexibly adjust experimental design, method selection, and data analysis to meet clients' requirements.

CD BioGlyco has professional technical talents and Glycosylation Inhibitor Development services, we have mature experience in the development of UDP-glucuronic acid inhibitors. Please feel free to contact us if you would like to acquire further information on inhibitor development.